News & Events

Viveve(R) Treatment Now Available in 28 Countries Throughout the World

SUNNYVALE, CA -- (Marketwired) -- 06/18/15 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced the expansion of its commercial efforts into Austria, Germany and Switzerland. In Austria and Germany, Viveve will partner with European Aesthetics, GmbH ("European Aesthetics"), a leading distributor of medical devices based in Schaafheim, Germany. Swiss distribution will be handled in partnership with Calista Medical, GmbH, ("Calista Medical") located in Frauenfeld, Switzerland.

Viveve now has 20 exclusive distribution partnerships covering 28 countries throughout the world:

               

REGION              COUNTRIES

                          

North America                     Canada

                 

Europe                                   United Kingdom, Ireland, Spain, The Netherlands, Belgium, Luxembourg,

Austria, Germany Switzerland

                                 

Asia Pacific                          Japan, Singapore, Malaysia, Vietnam, Brunei, Taiwan, Thailand, S. Korea

                                 

Middle East                           United Arab Emirates, Saudi Arabia, Lebanon, Kuwait, Bahrain, Qatar, Oman

  Jordan, Iraq, Egypt

"Germany, Austria and Switzerland represent important markets for Viveve. We're very pleased to be working with, what we believe, are two world-class partners to bring the globally patented Viveve System, which offers an effective and painless treatment for vaginal laxity, to physicians and their female patients in each country," said Patricia Scheller, the Chief Executive Officer of Viveve.

European Aesthetics works closely with its large network of key opinion leaders to identify emerging clinical needs and pioneering technologies to build new markets within Germany and Austria. "Now women who have this very common and frustrating condition will have access to a procedure that is aimed at improving vaginal laxity and restoring sexual satisfaction," said Ralf Schmidt, Founder and Chief Executive Officer.

Comprehensive training, strong customer support and innovative marketing are capabilities that have helped establish Calista Medical as a market leader in Switzerland. Luc Joosen, General Manager of Calista said, "The Viveve System is a perfect fit for Calista. It is in precise alignment with our goal of bringing innovative technologies to our physicians and their patients."

About Viveve

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

 

Contact:

Amato and Partners, LLC

Investor Relations Counsel

90 Park Avenue. 17th Floor

New York, NY 10016

212.430.0360

admin@amatoandpartners.com

 

Source: Viveve Medical, Inc.

 

Released June 18, 2015